Companies › Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MK-4002 (HPN217) Bispecific antibody targeting BCMA and CD3 | BCMA, CD3E | Phase 1 | Multiple Myeloma in Relapse | Dec 2026 |
| Gocatamig (HPN328, MK-6070) DLL3-targeted trispecific antibody | DLL3 | Phase 1 | Small-Cell Lung Cancer | Jan 2028 |
| Ifinatamab Deruxtecan (I-DXd, DS-7300a, MK-2400) Anti-CEACAM5 antibody-drug conjugate | CEACAM5 | Phase 1 | Small-Cell Lung Cancer | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04184050 | MK-4002 (HPN217) | Phase 1 | Multiple Myeloma in Relapse | Oncology | Dec 2026 |
| NCT04471727 | Gocatamig (HPN328, MK-6070) | Phase 1 | Small-Cell Lung Cancer | Oncology | Jan 2028 |
| NCT04471727 | Ifinatamab Deruxtecan (I-DXd, DS-7300a, MK-2400) | Phase 1 | Small-Cell Lung Cancer | Oncology | Jan 2028 |
Johnson & Johnson (Janssen) AbbVie Roche Chongqing Precision Biotech Regeneron Pharmaceuticals AstraZeneca Amgen Novartis Beijing Biotech iCell Gene Therapeutics
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.